Volume Alert - ARNA 4.20 Arena Pharmaceuticals $ARNA Hit a

New Post Public Reply Private Reply Replies (0) Message Board

Nov 19, 2014 at 2:06 PM

Volume Alert - ARNA 4.20 Arena Pharmaceuticals $ARNA Hit a high today of 4.32 Closing the day 10:30 at 4.20 -0.11 -2.55% With a day low of 4.19 and a total volume of 1,305,331.

ARNA Recent Posts: http://investorshangout.com/Arena-Pharmaceuti...RNA-53369/

ARNA Arena Pharmaceuticals Recent Headline News

Technical Updates on Biotech Stocks - ImmunoGen, Lexicon Pharma, ZIOPHARM Oncology, Arena Pharma, and Regulus Therapeutics
PR Newswire - Wed Nov 19, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regulus Therapeutics Inc. (NASDAQ: RGLS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, November 18, 2014, the NASDAQ Composite ended at 4,702.44, up 0.67%, the Dow Jones Industrial Average advanced 0.23%, to finish the day at 17,687.82, and the S&P 500 closed at 2,051.80, up 0.51%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 793.40, up 1.58%, with the index also advancing 12.08% in the last one month. Register for your complimentary reports on these five stocks at:
ZIOP: 3.66 (-0.06), LXRX: 1.27 (-0.02), IMGN: 9.50 (-0.18), RGLS: 16.63 (-1.49), ARNA: 4.10 (-0.21)

Arena Pharmaceuticals' (ARNA) Presents at Stifel Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Tue Nov 18, 10:42AM CST

ARNA: 4.10 (-0.21)

Janssen Is Working Its Way Toward Anti-Obesity
Spencer Osborne - at Seeking Alpha - Mon Nov 17, 4:14PM CST

ZFGN: 20.42 (-0.23), OREX: 5.70 (+0.08), NVO: 44.69 (+0.47), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)

EnteroMedics May Enter The Obesity Space - What Does It Mean?
Spencer Osborne - at Seeking Alpha - Mon Nov 17, 3:43PM CST

OREX: 5.70 (+0.08), ETRM: 1.31 (+0.01), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)

For This Obesity Drug, Europe Trumps the U.S.
Brian Orelli, The Motley Fool - Motley Fool - Mon Nov 17, 3:00PM CST
The launch of Orexigen Therapeutics ' obesity drug Contrave isn't off to the best start. As Chief Commercial Officer Mark Booth put it during the company's latest conference call: Unfortunately, like many new tactics, there have been some...
OREX: 5.70 (+0.08), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)

Belviq Weekly Sales Come In Flat
Spencer Osborne - at Seeking Alpha - Fri Nov 14, 3:58PM CST

ARNA: 4.10 (-0.21)

Belviq For Smoking Cessation - Sizzle Or Smolder?
Spencer Osborne - at Seeking Alpha - Fri Nov 14, 9:24AM CST

ARNA: 4.10 (-0.21)

ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination
Lance Brofman - at Seeking Alpha - Thu Nov 13, 8:52AM CST

OREX: 5.70 (+0.08), HLF: 38.87 (+0.55), NVO: 44.69 (+0.47), VVUS: 3.07 (+0.03), AMGN: 162.65 (+0.41), GSK: 46.38 (+0.10), ARNA: 4.10 (-0.21)

Arena Pharmaceuticals to Present at Stifel 2014 Healthcare Conference
PR Newswire - Thu Nov 13, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time), at The New York Palace Hotel in New York.
ARNA: 4.10 (-0.21)

Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:27AM CST
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?
ARNA: 4.10 (-0.21)

Arena Pharmaceuticals' (ARNA) Presents at Credit Suisse Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 9:32PM CST

ARNA: 4.10 (-0.21)

Bel-Phen Pilot Study News, Hold On To Your Shares
Rx Stocks - at Seeking Alpha - Tue Nov 11, 12:13PM CST

OREX: 5.70 (+0.08), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)

Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 10:15AM CST
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically, Arena Pharmaceuticals ' Belviq and VIVUS 's Qsymia reported a combined 283,000 prescriptions in the third quarter, with...
PFE: 30.36 (-0.23), VVUS: 3.07 (+0.03), GSK: 46.38 (+0.10), ARNA: 4.10 (-0.21)

Why Orexigen Therapeutics, Inc. Stock Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Mon Nov 10, 5:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Orexigen Therapeutics , a...
OREX: 5.70 (+0.08), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)

Arena And Vivus Investors Need To Watch Orexigen
Spencer Osborne - at Seeking Alpha - Mon Nov 10, 12:24PM CST

OREX: 5.70 (+0.08), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)

Orexigen rises as weight loss drug review proceeds
AP - Mon Nov 10, 10:02AM CST
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 5.70 (+0.08), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)

Belviq Sales Dip Slightly - Quarter Is Flat Thus Far
Spencer Osborne - at Seeking Alpha - Fri Nov 07, 12:02PM CST

VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)

Vivus Beats The Street On Milestone Payment For ED Drug
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:59AM CST

OREX: 5.70 (+0.08), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)

Will Belviq Advertising Pick Up Again?
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:55AM CST

VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)

Lorcaserin HCl Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases
PR Newswire - Thu Nov 06, 7:00AM CST
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 7-11, 2014, in Boston, Massachusetts.
ARNA: 4.10 (-0.21)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Honoring Dr. Drew's Impact on Blood Banking History

Legacy of Dr. Charles R. Drew Comes Alive Here's one for the books: a legacy that's still saving lives 85 years after it began. Dr. Charles R. Drew, the mastermind behind blood banking, is getting his due respect with a documentary called Iconic Excellence. No fluff here—this film unveils how the man's breakthroughs during World War II laid down the bedrock of modern...

Aesthetic M&A: Graper Harper's New Future Unfolds

Charlotte's Premier Practice Takes a Strategic Leap Graper Harper Cosmetic Surgery's recent partnership with Aesthetic Partners might not be the headline grabbing Wall Street tale we've grown accustomed to, but it's certainly worth noting. When a practice like Graper Harper, recognized as a jewel in Charlotte's cosmetic landscape, teams up with a player like Aesthetic...

Syra Health Joins CMS ACCESS Model for Scalable Growth

Syra Health Secures Spot in CMS ACCESS Model Every once in a while, a company gets a nod that could redefine its trajectory, and today it’s Syra Health’s turn at bat. Teaming up with HealthSync, they’ve clinched a position in the coveted CMS ACCESS model—a move not just about snagging headlines but potentially securing a golden ticket to a robust revenue stream...

Flex Acquires EPC Power in a $4.4 Billion Deal

An Acquisition with Enormous Implications Folks, if you haven't been paying attention, you're missing out on a seismic shift. EPC Power's sale to Flex for a hefty $4.4 billion isn't just another transaction; it's a clear signal of where the future's headed, especially if you're plugged into the energy or tech sectors. With the way AI is guzzling power like a thirsty...

Lundbeck's Bexicaserin Insights Rock Epilepsy Congress

Breaking Down Bexicaserin's Dual Action Seems like Lundbeck's playing the long game with bexicaserin, and boy, are they shaking things up at the European Epilepsy Congress. This isn't your usual sit-back-and-watch situation. They're putting bexicaserin's dual mode of action under a magnifying glass, aiming to hit both sides of the brain's seesaw by increasing inhibitory...

Safety and Wellbeing as Key Business Strategy Focus

Revolutionizing Safety in the Workplace Cracking the typical mindset of treating employee safety as a checkbox item, Debra Wein, CEO and Founder of Wellness Workdays, is set to shake up the NSC Safety Congress & Expo. Her upcoming session, titled "Transforming Safety and Wellbeing into a Competitive Business Advantage," isn't just a run-of-the-mill talk. It's a call to...

PinkBlush Maternity Unveils Its 2026 Fall Fashion Line

Elevating Maternity Fashion with PinkBlush's Fall 2026 Line You know, it's not every day you see maternitywear aiming to push the envelope, but that's exactly what PinkBlush is doing this fall. They've unleashed their Fall 2026 collection, and let's just say, it's less about the frills and more about redefining what expecting mothers can expect from the fashion world. A...

Curve Memberships: A New Path for Dental Practices

Revolutionizing Dental Practice Management Ever met a dentist who says they love dealing with insurance bureaucracies? Yeah, me neither. Curve Dental's latest gambit into membership plans is aiming to slice right through that mess. They've launched a shiny new component aptly named Curve Memberships. This isn't just some fly-by-night addon; it's about deep...

Triskell Debuts in Gartner's 2026 Magic Quadrant

Triskell Software Makes Its Mark Kicking off September 2026 with a bang, Triskell Software finds itself on the illustrious 2026 Gartner Magic Quadrant for Adaptive Project Management and Reporting (APMR). This marks the first time the Madrid-based company nabs a spot here, and it's a significant feather in their cap. Just think, out of the 11 vendors invited to this...

Ribbonwire Ranch Hits Sheetz Milestone with Campaign

Where Beef Snacks Meet Road Tales Just a year ago, Ribbonwire Ranch, a small Texas-based beef snack producer, made its debut at Sheetz stores. Now, they're not just another brand on the shelf; they're weaving tales from the road with their latest venture, the "Dashboard Diaries" campaign. If you're wondering how a beef snack producer finds itself in an eight-week...